Searched for: subject%3A%22Antiplasmin%22
(1 - 20 of 22)

Pages

List view
Grid view
document
Norris, L.A. (author), Brosnan, J. (author), Bonnar, J. (author), Conard, J. (author), Kluft, C. (author), Hellgren, M. (author), TNO Kwaliteit van Leven (author)
Epidemiological studies have shown that hormone therapy (HT) increases the risk of venous thromboembolism in post menopausal women. The mechanism of this increased risk is unknown; however, activation of the haemostatic system is known to contribute to the pathogenesis of venous thromboembolism. In post-menopausal women the estrogen /progestogen...
article 2008
document
TNO Preventie en Gezondheid (author), Meijers, J.C.M. (author), Oudijk, E.J.D. (author), Mosnier, L.O. (author), Bos, R. (author), Bouma, B.N. (author), Nieuwenhuis, H.K. (author), Fijnheer, R. (author)
Acute promyelocytic leukaemia (APL) is a disease that is distinguished from other leukaemias by the high potential for early haemorrhagic death. Several processes are involved, such as disseminated intravascular coagulation and hyperfibrinolysis. Recently, TAFI (thrombin-activatable fibrinolysis inhibitor) was identified as a link between...
article 2000
document
Clason, S.B. (author), Meijer, P. (author), Kluft, C. (author), Ersdal, E. (author), Gaubius instituut TNO (author)
Recently, a chromogenic kit for determination of plasmin inhibitor activity, Coamatic® Plasmin Inhibitor, has been developed with the aim to increase specificity and to allow application to a wide range of automates. The highly sensitive plasmin substrate S-2403 is used and, to further improve specificity, a low level of plasmin and a short...
article 1999
document
Leebeek, F.W.G. (author), Los, P. (author), Kluft, C. (author), Gaubius Instituut TNO (author)
We have studied the plasminogen-binding and non-binding molecular forms of α2-antiplasmin (α2-AP), the major inhibitor of plasmin, using a modification of the crossed immunoelectrophoresis technique (mCIE). The previous technique using addition of Lys-plasminogen to the gel of the first dimension electrophoresis was simplified using commercially...
article 1996
document
Clason, S.B. (author), Meijer, P. (author), Kluft, C. (author), Ersdal, E. (author), Gaubius Instituut TNO (author)
A new automated method, COAMATIC® Plasmin Inhibitor, provides a tool for specific determination of Plasmin Inhibitor activity in plasma. The method is adapted to the ACL 300R, Cobas Mira, MLA 1000C and to the Thrombolyzer. Low plasmin concentrations combined with short incubation times ensure good specificity also in the low range, resulting in...
article 1996
document
Biasucci, L.M. (author), de Maat, M.P.M. (author), Meo, A. (author), van der Greet, W. (author), Summaria, F. (author), Quaranta, G. (author), Liuzzo, G. (author), Kluft, C. (author), Maseri, A. (author), Gaubius Instituut TNO (author)
In order to investigate the role of the hemostatic, fibrinolytic and inflammatory system in unstable angina, we assessed the levels of thrombin-antithrombin III (TAT), Prothrombin Fragment 1+2 (F1+2), plasmin-antiplasmin (PAP) and D-Dimer (DD) and of C-reactive protein (CRP) in 51 patients admitted to our CCU with severe unstable angina. Thirty...
article 1996
document
Meijer, P. (author), Kluft, C. (author), Gaubius Laboratory TNO Preventie en Gezondheid (author)
Test procedures of several commercially available functional test kits for α2-antiplasmin were investigated. The importance of the plasmin concentration, the amount of plasma used in the test and the preincubation time for a specific test for the determination of α2-antiplasmin were discussed. A Specific Plasmin Inhibition Test (SPIT) suitable...
article 1996
document
Rijken, D.C. (author), Groeneveld, E. (author), Barrett-Bergshoeff, M.M. (author), Gaubius Laboratory TNO Preventie en Gezondheid (author)
BM 06.022 is a non-glycosylated mutant of human tissue-type plasminogen activator (t-PA) comprising only the kringle-2 and proteinase domains. The in vivo half-life of BM 06.022 antigen is 4- to 5-fold longer than that of t-PA antigen. The in vitro half-life of the activity of BM 06.022 at therapeutic concentrations in plasma is shorter than...
article 1994
document
Meijer, P. (author), Westerveld, W. (author), Huisman, L.G.M. (author), Gaubius Laboratory TNO Preventie en Gezondheid (author)
Comparison of the results for α2-antiplasmin activity of plasma samples (n = 61, range 0-125%) obtained by the 'immediate plasmin inhibition test' (IPIT) and by the automated method for the MLA Electra 1000C of Dade® shows a good correlation (R = 0.935) but a systematic disagreement especially relevant in the range below 40%. An improved method...
article 1994
document
Haan, J. (author), Kluft, C. (author), Leebeek, F.W.G. (author), de Bart, A.C.W. (author), Buruma, O.J. (author), Roos, R.A.C. (author)
In view of reported associations between increased bleeding tendency and systemically decreased alpha 2-antiplasmin in patients with systemic amyloid deposition we studied alpha 2-antiplasmin, fibrinogen, C-reactive protein and blood levels of locally produced endothelial hemostasis factors in the acute and quiescent phase in 16 patients with...
article 1992
document
Kooistra, T. (author), van Bennekum, A.M. (author), Hendriks, H.F.J. (author), Brouwer, A. (author), Roholl, P.J.M. (author), Emeis, J.J. (author), Netherlands Instituut voor Verouderings- en Vaatziekten Onderzoek TNO (author)
article 1992
document
Emeis, J.J. (author), Verheijen, J.H. (author), Instituut voor Verouderings- en Vaatziekten Onderzoek TNO (author)
Chemicals/CAS: Recombinant Proteins; Tissue Plasminogen Activator, EC 3.4.21.68
article 1992
document
de Fouw, N.J. (author), Haverkate, F. (author), Bertina, R.M. (author), Gaubius Instituut TNO (author)
The effect of purifed human activated protein C (APC) on fibrinolysis was studied by using in vitro clot lysis techniques. Clots were formed from citrated blood or plasma (supplemented with 125I-labeled fibrinogen) by adding thrombin and Ca2+-ions; lysis of the clots was achieved by the addition of tissue-type plasminogen activator before clot...
article 1991
document
Padro, T. (author), van den Hoogen, C.M. (author), Emeis, J.J. (author), Gaubius Instituut TNO (author)
Plasmin inhibition by rat tissue extracts were compared with rat plasma plasmin inhibition. Nine different tissues were extracted with an acid acetate-buffer (lung, heart, brain, adrenal, aorta, skeletal muscle, spleen and liver) or with KSCN-buffer (kidney), and antiplasmin activity was evaluated by a spectrophotometric method. All tissue...
article 1991
document
Gaubius Instituut TNO (author), Rijken, D.C. (author), Groeneveld, E. (author), Kluft, C. (author), Nieuwenhuis, H.K. (author)
α2-Antiplasmin Enschede is a variant of α2-antiplasmin which has lost its ability to inhibit plasmin irreversibly and which is associated with haemorrhagic disorder [Kluft et al. (1987) J. Clin. Invest. 80, 1391-1400]. The abnormal protein was purified from the plasma of a homozygous patient and subjected to one-dimensional peptide mapping using...
article 1988
document
Gaubius instituut TNO (author), Kluft, C. (author)
Fibrinolytic agents used in intravenous thrombolytic therapy of myocardial infarction also exert, at effective dosages, significant side effects on the haemostatic system outside the direct resolution of the target thrombus. The side effects of the agents streptokinase and anisoylated plasminogen-streptokinase activator complex are larger than...
article 1988
document
Kluft, C. (author), Nieuwenhuis, H.K. (author), Rijken, D.C. (author), Groeneveld, E. (author), Wijngaards, G. (author), van Berkel, W. (author), Dooijewaard, G. (author), Sixma, J.J. (author), Gaubius instituut TNO (author)
??2-Antiplasmin (??2-AP) is a major fibrinolysis inhibitor, whose complete, congenital absence has been found to be associated with a distinct hemorrhagic diathesis. We studied a 15-yr-old male with a hemorrhagic diathesis after trauma from early childhood on. This bleeding tendency was associated with a minimal ??2-AP level recorded...
article 1987
document
Gezondheidsorganisatie TNO Gaubius Instituut TNO (author), van Leebeek, F.W.G. (author), Stibbe, J. (author), Knot, E.A.R. (author), Gomes, M.J. (author), Beudeker, M. (author)
conference paper 1987
document
Kluft, C. (author), Los, P. (author), Jie, A.F.H. (author), Gaubius instituut TNO (author)
Alpha-2-antiplasmin, a major inhibitor of fibrinolysis, is synthesized in the liver and occurs in blood in two molecular forms: a very active plasminogen-binding (PB) form and a less active nonplasminogen-binding (NPB) form. This study investigated the origin and mutual relationship of these two forms in vivo and in vitro. Despite wide variation...
article 1986
document
Kluft, C. (author), Vellenga, E. (author), Brommer, E.J.P. (author), Wijngaards, G. (author), Gaubius instituut TNO (author)
This study concerns a case of congenital homozygous deficiency in ??2-antiplasmin associated with a severe hemorrhagic diathesis. Heterozygous family members also show a mild bleeding tendency. The propositus is a 17-yr-old male born of white parents and showing a severe hemorrhagic diathesis characterized by spontaneous bleeding in the joints...
article 1982
Searched for: subject%3A%22Antiplasmin%22
(1 - 20 of 22)

Pages

List view
Grid view